FIELD: medicine, cardiology, pharmacy. SUBSTANCE: invention relates to treatment of patients with cardiovascular diseases where the use of the preparation ranolasin is prescribed. Invention proposes to administrate the ranolasin pharmaceutical form providing the sustained- -release of indicated medicinal agent. Administration should be carried out to provide maintenance of ranolasin level in human blood plasma in the range 550-7500 ng/ml. Invention proposes to use medicinal form providing at least 50 weight % of ranolasin and pH-dependent binding agent inhibiting release of ranolasin in stomach. Method provides stable therapeutic effect of the preparation enhancing effectiveness of treatment of patients with indicated diseases, in particular, stenocardia. EFFECT: enhanced effectiveness of treatment, valuable medicinal properties of agent. 43 cl, 9 tbl, 8 ex
